<DOC>
	<DOC>NCT01211145</DOC>
	<brief_summary>The purpose of this study is to investigate if ZomigÂ® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).</brief_summary>
	<brief_title>Zomig - Treatment of Acute Migraine Headache in Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Provision of written informed consent by parent or legal guardian, and written assent provided by patient prior to any study specific procedures. Established diagnosis of migraine. History of a minimum of 2 migraine attacks (moderately or severely disabling)per month. Any medical condition that may put the patient at increased risk with exposure to zolmitriptan or that may interfere with the safety or efficacy assessments. A history of basilar, ophthalmoplegic, or hemiplegic migraine headache or any potentially serious neurological condition that is associated with headache. Have had an unacceptable adverse experience following previous use of any 5HT1B/1D agonist drug.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Pain</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Adolescents</keyword>
</DOC>